nderstanding the role of Cyclosporin A drops in control of ocular inflammation in acute cases of Stevens Johnson Syndrome

Completed

• Conditions: Skin and Connective Tissue Diseases; Acute Stevens-Johnson Syndrome; Stevens-Johnson syndrome

• Registration Number: ISRCTN11036223
• Lead Sponsor: All India Institute of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-10-03
• Last Update Posted: 7 November 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients of acute Stevens Johnson Syndrome

Exclusion Criteria

1. Pregnant females
2. Lactating females
3. Children below 2 years
4. Patients who refuse consent
5. Patients with known sensitivity to cyclosporin
6. Patients with cardiac, renal and hepatic failure

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Degree of inflammation, assessed using grading score for inflammation (conjunctival hyperaemia)<br>2. Degree of corneal vascularisation, assessed using grading score for corneal vascularisation<br><br>Measured pre-treatment and post treatment.

Secondary Outcome Measures

Name	Time	Method
1. Any improvement in tear secretions, assessed using schirmer’s test <br>2. Ocular surface status, assessed using overall grading for ocular surface parameters<br><br>Measured pre-treatment and post treatment.